Skip to main content

Advertisement

Table 1 Clinical, demographic characteristics and systemic disease activity indexes of psoriatic arthritis patients

From: Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint

Knee Disease duration (years) Gonarthritis duration (years) Treatment at study entry ESR CRP DAS mRAI
     PRE POST PRE POST PRE POST PRE POST
1 10.3 10.3 MTX; PN 46.4 88.4 1.78 0.33 3.21 3.42 8 8
2 8.4 6.4 PN;MTX;CSA;E 40.3 29.0 2.77 0.72 3.44 3.33 12 12
3 12.5 10.5 PN 23.2 22.2 0.53 0.02 2.33 1.25 3 0
4 8.6 8.6 LEF;E 72.5 33.8 0.56 0.56 2.78 2.59 4 4
5 22 5.7 PN 12.0 13.0 0.85 0.53 2.88 2.47 6 5
6 11 11 MTX 15.6 22.7 0.10 0.00 2.69 3.00 7 9
7 9 9 SSZ 15.0 11.0 0.66 0.39 3.18 2.42 12 5
8 6.5 4.3 MTX; PN; E 6.0 9.9 0.32 0.80 2.65 1.87 10 2
9 4 3.5 MTX; SSZ 18.1 3.6 2.93 0.24 2.52 0.71 5 0
10 9 15 CSA;PN; E 30.0 20.0 0.00 0.00 3.01 2.40 2 1
11 4.8 4.5 MTX;CSA 29.4 25.2 0.08 0.08 2.48 1.89 4 1
12 2.5 2.5 MTX; PN 14.3 6.8 0.70 0.20 3.97 3.40 20 18
13 8.5 2 SSZ; MTX 41.2 27.2 0.48 0.14 2.77 1.98 3 1
14 5.5 3.5 SSZ 13.6 2.2 0.26 0.26 3.22 0.75 9 0
  1. CRP, C-reactive protein (≤ 0.5 mg/dl); CSA, cyclosporin; DAS, disease activity score; E, etanercept; ESR, erythrocyte sedimentation rate (≤ 28 mm/h); HCQ, hydroxychloroquine; LEF, lefluonomide; mRAI, modified Ritchie articolar index; MTX, methotrexate; PN, prednisone; PsA, psoriatic arthritis; Pt, patient; SSZ, sulphasalazine.